<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05090891</url>
  </required_header>
  <id_info>
    <org_study_id>INCB 00928-201</org_study_id>
    <nct_id>NCT05090891</nct_id>
  </id_info>
  <brief_title>To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva</brief_title>
  <official_title>A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Incyte Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Incyte Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 2, Randomized, Double-Blind, Placebo-Controlled Study is intended to evaluate the&#xD;
      Efficacy, Safety, and Tolerability and PK of INCB000928 administered to participants with a&#xD;
      clinical diagnosis of fibrodysplasia ossificans progressiva (FOP).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 20, 2021</start_date>
  <completion_date type="Anticipated">October 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">November 5, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Double Blind Period: Total volume of new heterotopic ossification (HO)</measure>
    <time_frame>Week 24</time_frame>
    <description>HO will be assessed by low dose whole-body computed tomography (WBCT) (excluding the head) compared to baseline during the double-blind period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Double-blind Period: Total number of new flares</measure>
    <time_frame>Baseline, Week 12 and Week 24</time_frame>
    <description>Defined as number of new flares compared to baseline during the double-blind period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Double-blind Period: Proportion of participants with a clinically meaningful improvement in the flare-related symptoms</measure>
    <time_frame>Baseline, Week 12 and Week 24</time_frame>
    <description>Flare related symptoms will be assessed by via an electronic PRO during the double-blind period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Treatment Emergent Adverse Events (TEAE)</measure>
    <time_frame>Up to 80 weeks</time_frame>
    <description>Defined as any adverse event either reported for the first time or worsening of a pre-existing event after first dose of study drug.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Fibrodysplasia Ossificans Progressiva (FOP)</condition>
  <arm_group>
    <arm_group_label>Group A: INCB000928</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive INCB000928 for 24 weeks (double-blind period). Participants who complete the double-blind period will continue into open-label extension period for an additional 52 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B: Placebo followed by INCB000928</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo for 24 weeks (double-blind period). Participants who completed the double-blind period will receive INCB000928 in the 52 week open-label extension period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INCB000928</intervention_name>
    <description>INCBG000928 will be administered QD orally.</description>
    <arm_group_label>Group A: INCB000928</arm_group_label>
    <other_name>INB000928 will be administered QD orally</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo will be administered QD orally</description>
    <arm_group_label>Group A: INCB000928</arm_group_label>
    <arm_group_label>Group B: Placebo followed by INCB000928</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female and male adults and adolescents ≥ 12 years of age with a diagnosis of FOP.&#xD;
&#xD;
          -  Willingness to avoid pregnancy or fathering children based on the criteria below.&#xD;
&#xD;
          -  Willing and able to undergo low-dose WBCT (excluding the head) imaging without&#xD;
             requiring intubation.&#xD;
&#xD;
          -  Further inclusion criteria apply.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breast-feeding.&#xD;
&#xD;
          -  CAJIS score ≥ 24.&#xD;
&#xD;
          -  FOP disease severity that in the investigator's opinion precludes participation.&#xD;
&#xD;
          -  Any clinically significant medical condition other than FOP that would, in the&#xD;
             investigator's judgment, interfere with full participation in the study, pose a&#xD;
             significant risk to the participant, or interfere with interpretation of study data.&#xD;
&#xD;
          -  Chronic or current active infectious disease requiring systemic antibiotic,&#xD;
             antifungal, or antiviral treatment.&#xD;
&#xD;
          -  HIV, HBV, or HCV infection. Note:&#xD;
&#xD;
          -  Further exclusion criteria apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kurt Brown, MD</last_name>
    <role>Study Director</role>
    <affiliation>Incyte Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Incyte Corporation Call Center (US)</last_name>
    <phone>1.855.463.3463</phone>
    <email>medinfo@incyte.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Incyte Corporation Call Center (ex-US)</last_name>
    <phone>+800 00027423</phone>
    <email>eumedinfo@incyte.com</email>
  </overall_contact_backup>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 8, 2021</study_first_submitted>
  <study_first_submitted_qc>October 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2021</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>fibrodysplasia ossificans progressiva (FOP)</keyword>
  <keyword>heterotopic ossification</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myositis Ossificans</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.</ipd_time_frame>
    <ipd_access_criteria>Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://www.incyte.com/our-company/compliance-and-transparency</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

